Sources/Clones
Axcel/Accurate (polyclonal), Biogenesis, Biogenex (130-137), Biomedia/Accurate (MAB3), Biosource, Biotec, Boehringer Mannheim, Cymbus (MIG-MI9), Dako, Research Diagnostics (MIG-MI9), Serotec and Zymed (polyclonal).
Fixation/Preparation
The antigen is formalin resistant and its immunoreactivity is enhanced by proteolytic digestion or HIER. The antibody can be applied to frozen sections.
Background
Myelin basic protein (MBP) is found in the central and peripheral system. It is found in oligodendrocytes and myelin of white matter in the brain and spinal cord and to a lesser extent in gray matter. It is also found in peripheral nerve.
Applications
MBP is useful in research but has limited applications in diagnostic immunohistochemistry where its use is largely in the diagnosis of soft tissue tumors. It has been demonstrated in neuromas, neurofibromas, ganglioneuromas and tumors with neural differentiation and neural elements but is not present in glial tissues. The protein has been employed in a panel of antibodies to identify palisaded encapsulated neuromas of the skin (Argenyi, 1990) and is useful for the distinction of neurofibromas from neurotized melanocytic nevi. Neurofibromas showed focal staining for CD 57 (Leu 7), glial fibrillary acidic protein and MBP whereas neurotized nevi failed to express these markers (Gray et al, 1990). MBP (together with CD 57) has also been demonstrated in some granular cell tumors (Mazur et al, 1990), suggesting neural differentiation in some of these lesions. MBP is a useful marker of ganglioneuroblastomas, ganglioneuromas and gangliocytic paraganglioma (Furihata et al, 1996; Molenaar et al, 1990).
Comments
The use of MBP as a marker of Schwannomas is well established (Wick et al, 1987) although some studies have failed to find MBP in Scwann cell neoplasms (Clark et al, 1985; Johnson et al, 1988; Sharma et al, 1990) and both immunohistochemical and Western blot analyses have failed to demonstrate MBP in oligodendrogliomas and Schwann cell tumors (Schwechheimer et al, 1992). Other markers such as S100, fibrillary acidic protein and CD 57 are preferred for the characterization of nerve sheath differentiation.
References
•Immunohistochemical characterization of palisaded encapsulated neuroma. Journal of Cutaneous Pathology 17: 329-335.
•Clark HB, Minesky JJ, Agrawal D, Agarawal HC 1985. Myelin basic protein and P2 protein are not immunohistochemical markers for Schwann cell neoplasms. A comparative study using antisera to S100, P2, and myelin basic proteins. American Journal of Pathology 121: 96-101.
•Furihata M, Sonobe H, Iwata J et al 1996. Immunohistochemical characterization of a case of duodenal gangliocytic paraganglioma. Pathology International 46: 610-613. gangliocytic paraganglioma. Pathology International 46: 610-613.
•Gray MH, Smoller BR, McNutt NS, Hsu A 1990. Neurofibromas and neurotized melanocytic nevi are immunohistochemcally distinct neoplasms. American Journal of Dermatopathology 12: 234-241.
•Johnson MD, Glick AD, Davis BW 1988. Immunohistochemical evaluation of Leu 7, myelin basic protein, S100- protein, glial fibrillary acidic-protein, and LN3 immunoreactivity in nerve sheath tumors and sarcomas. Archives of Pathology and Laboratory Medicine 112: 155-160.
•Mazur MT, Schultz JJ, Myers JL 1990. Granular cell tumor - immunohistochemical analysis of 21 benign and one maligant tumor. Archives of Pathology and Laboratory Medicine 114: 692-696.
•Molenaar WM, Baker DL, Pleasure D et al 1990. The neuroendocrine and neural profiles of neuroblastomas, ganglioneuroblastomas, and ganglioneuromas. American Journal of Pathology 136: 375-382.
•Schwechheimer K, Gass P, Berlet HH 1992. Expression of oligodendroglia and Schwann cell markers in human nervous system tumors. An immunomorphological study and western blot analysis. Acta Neuropathologica (Berlin) 83: 283-291.
•Sharma S, Sarkar C, Mathur M, et al 1990. Benign nerve sheath tumors: a light microscopic, electron microscopic and immunohistochemical study of 102 cases. Pathology 22: 191-195.
•Wick MR, Swanson PE, Scheithauer BW, Manival JC 1987. Malignant peripheral nerve sheath tumor: an immunohistochemical study of 62 cases. American Journal of Clinical Pathology 87: 425-433.
Bibliografia
Manual of diagnostic antibodies for immunohistology / Anthony S.-Y. Leong, Kumarasen Cooper, F. Joel W.-M. Leong.
Axcel/Accurate (polyclonal), Biogenesis, Biogenex (130-137), Biomedia/Accurate (MAB3), Biosource, Biotec, Boehringer Mannheim, Cymbus (MIG-MI9), Dako, Research Diagnostics (MIG-MI9), Serotec and Zymed (polyclonal).
Fixation/Preparation
The antigen is formalin resistant and its immunoreactivity is enhanced by proteolytic digestion or HIER. The antibody can be applied to frozen sections.
Background
Myelin basic protein (MBP) is found in the central and peripheral system. It is found in oligodendrocytes and myelin of white matter in the brain and spinal cord and to a lesser extent in gray matter. It is also found in peripheral nerve.
Applications
MBP is useful in research but has limited applications in diagnostic immunohistochemistry where its use is largely in the diagnosis of soft tissue tumors. It has been demonstrated in neuromas, neurofibromas, ganglioneuromas and tumors with neural differentiation and neural elements but is not present in glial tissues. The protein has been employed in a panel of antibodies to identify palisaded encapsulated neuromas of the skin (Argenyi, 1990) and is useful for the distinction of neurofibromas from neurotized melanocytic nevi. Neurofibromas showed focal staining for CD 57 (Leu 7), glial fibrillary acidic protein and MBP whereas neurotized nevi failed to express these markers (Gray et al, 1990). MBP (together with CD 57) has also been demonstrated in some granular cell tumors (Mazur et al, 1990), suggesting neural differentiation in some of these lesions. MBP is a useful marker of ganglioneuroblastomas, ganglioneuromas and gangliocytic paraganglioma (Furihata et al, 1996; Molenaar et al, 1990).
Comments
The use of MBP as a marker of Schwannomas is well established (Wick et al, 1987) although some studies have failed to find MBP in Scwann cell neoplasms (Clark et al, 1985; Johnson et al, 1988; Sharma et al, 1990) and both immunohistochemical and Western blot analyses have failed to demonstrate MBP in oligodendrogliomas and Schwann cell tumors (Schwechheimer et al, 1992). Other markers such as S100, fibrillary acidic protein and CD 57 are preferred for the characterization of nerve sheath differentiation.
References
•Immunohistochemical characterization of palisaded encapsulated neuroma. Journal of Cutaneous Pathology 17: 329-335.
•Clark HB, Minesky JJ, Agrawal D, Agarawal HC 1985. Myelin basic protein and P2 protein are not immunohistochemical markers for Schwann cell neoplasms. A comparative study using antisera to S100, P2, and myelin basic proteins. American Journal of Pathology 121: 96-101.
•Furihata M, Sonobe H, Iwata J et al 1996. Immunohistochemical characterization of a case of duodenal gangliocytic paraganglioma. Pathology International 46: 610-613. gangliocytic paraganglioma. Pathology International 46: 610-613.
•Gray MH, Smoller BR, McNutt NS, Hsu A 1990. Neurofibromas and neurotized melanocytic nevi are immunohistochemcally distinct neoplasms. American Journal of Dermatopathology 12: 234-241.
•Johnson MD, Glick AD, Davis BW 1988. Immunohistochemical evaluation of Leu 7, myelin basic protein, S100- protein, glial fibrillary acidic-protein, and LN3 immunoreactivity in nerve sheath tumors and sarcomas. Archives of Pathology and Laboratory Medicine 112: 155-160.
•Mazur MT, Schultz JJ, Myers JL 1990. Granular cell tumor - immunohistochemical analysis of 21 benign and one maligant tumor. Archives of Pathology and Laboratory Medicine 114: 692-696.
•Molenaar WM, Baker DL, Pleasure D et al 1990. The neuroendocrine and neural profiles of neuroblastomas, ganglioneuroblastomas, and ganglioneuromas. American Journal of Pathology 136: 375-382.
•Schwechheimer K, Gass P, Berlet HH 1992. Expression of oligodendroglia and Schwann cell markers in human nervous system tumors. An immunomorphological study and western blot analysis. Acta Neuropathologica (Berlin) 83: 283-291.
•Sharma S, Sarkar C, Mathur M, et al 1990. Benign nerve sheath tumors: a light microscopic, electron microscopic and immunohistochemical study of 102 cases. Pathology 22: 191-195.
•Wick MR, Swanson PE, Scheithauer BW, Manival JC 1987. Malignant peripheral nerve sheath tumor: an immunohistochemical study of 62 cases. American Journal of Clinical Pathology 87: 425-433.
Bibliografia
Manual of diagnostic antibodies for immunohistology / Anthony S.-Y. Leong, Kumarasen Cooper, F. Joel W.-M. Leong.
